These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Klawiter EC; Cross AH; Naismith RT Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
5. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
6. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications. Pittock SJ; Rodriguez M Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812 [TBL] [Abstract][Full Text] [Related]
7. [Choice of early and escalation treatment options for multiple sclerosis]. Linker RA; Kieseier BC Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985 [TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Fox RJ; Bethoux F; Goldman MD; Cohen JA Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920 [TBL] [Abstract][Full Text] [Related]
9. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
11. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapies in neurologic disorders. Graves D; Vernino S Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853 [TBL] [Abstract][Full Text] [Related]
18. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. Pawate S; Wang L; Song Y; Sriram S J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826 [TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Clegg A; Bryant J Expert Opin Pharmacother; 2001 Apr; 2(4):623-39. PubMed ID: 11336612 [TBL] [Abstract][Full Text] [Related]
20. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S; Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241 [No Abstract] [Full Text] [Related] [Next] [New Search]